FMO5 and endothelial dysfunction: Locally in the arteries, hs-CRP not only inhibits the release of nitric oxide (NO) and vascular dilation but also enhances NADPH oxidase activity in the arterial endothelium, promoting the generation of superoxide and subsequently triggering endothelial dysfunction, thereby exerting pro-inflammatory and pro-atherosclerotic effects (39).